Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Arevirumab-3 Humanized Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA5-54837
产品规格
种属反应
Virus
宿主/亚型
Human
/ IgG1, kappa
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
抗原
Recombinant LASV GPC.
偶联物
形式
Liquid
浓度
1.8 mg/mL
纯化类型
Protein A/G
保存液
PBS
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
RRID
产品详细信息
Compatible with Direct ELISA
靶标信息
Arevirumab-3, also known as Arevirumab, is a broadly neutralizing human monoclonal antibody developed to treat advanced stages of Lassa virus infections. Lassa virus (LASV) is an enveloped, segmented RNA virus belonging to the family Arenaviridae, genus Mammarenavirus. It is classified within the Old World mammarenaviruses which include other viruses like the lymphocytic choriomeningitis virus, Mopeia virus, and Lujo virus. LASV circulates predominantly in West and Central Africa and has been causing zoonotic infections in humans for centuries, primarily transmitted through contact with the urine or feces of infected rodents. The virus is responsible for Lassa fever, a severe viral hemorrhagic fever (VHF) with a significant case-fatality rate among hospitalized patients, reported to be around 20% or higher. Of those infected, approximately 80% exhibit mild or no symptoms, while the remaining 20% progress to severe disease necessitating hospitalization.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
